BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37151285)

  • 21. PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.
    Madore J; Strbenac D; Vilain R; Menzies AM; Yang JY; Thompson JF; Long GV; Mann GJ; Scolyer RA; Wilmott JS
    Clin Cancer Res; 2016 Aug; 22(15):3915-23. PubMed ID: 26960397
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1
    Saito R; Abe H; Kunita A; Yamashita H; Seto Y; Fukayama M
    Mod Pathol; 2017 Mar; 30(3):427-439. PubMed ID: 27934877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of Her2-low in colorectal cancer and its relations with the tumor microenvironment.
    Lang-Schwarz C; Vieth M; Dregelies T; Sterlacci W
    Pathol Res Pract; 2023 Apr; 244():154417. PubMed ID: 36947983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation.
    Srivastava P; Husain N; Shukla S; Chauhan S; Pandey A; Masood S
    Indian J Pathol Microbiol; 2021; 64(3):490-496. PubMed ID: 34341259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
    Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
    Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients.
    Dong Z; Kong L; Wan Z; Zhu F; Zhong M; Lv Y; Zhao P; Shi H
    Sci Rep; 2019 Nov; 9(1):16894. PubMed ID: 31729406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value.
    Kim A; Lee SJ; Kim YK; Park WY; Park DY; Kim JY; Lee CH; Gong G; Huh GY; Choi KU
    Sci Rep; 2017 Sep; 7(1):11671. PubMed ID: 28916815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers.
    Kim JH; Park HE; Cho NY; Lee HS; Kang GH
    Br J Cancer; 2016 Aug; 115(4):490-6. PubMed ID: 27404452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of comprehensive genomic sequencing for detecting HER2-positive colorectal cancer.
    Shimada Y; Yagi R; Kameyama H; Nagahashi M; Ichikawa H; Tajima Y; Okamura T; Nakano M; Nakano M; Sato Y; Matsuzawa T; Sakata J; Kobayashi T; Nogami H; Maruyama S; Takii Y; Kawasaki T; Homma KI; Izutsu H; Kodama K; Ring JE; Protopopov A; Lyle S; Okuda S; Akazawa K; Wakai T
    Hum Pathol; 2017 Aug; 66():1-9. PubMed ID: 28235632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
    Zeng L; Koh VCY; Chen XY; Tan PH
    Histopathology; 2023 Apr; 82(5):779-788. PubMed ID: 36635954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 overexpression/amplification status in colorectal cancer: a comparison between immunohistochemistry and fluorescence in situ hybridization using five different immunohistochemical scoring criteria.
    Sun Q; Li Q; Gao F; Wu H; Fu Y; Yang J; Fan X; Cui X; Pu X
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):579-592. PubMed ID: 36018511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer.
    Li Z; Lai Y; Sun L; Zhang X; Liu R; Feng G; Zhou L; Jia L; Huang X; Kang Q; Lin D; Gao J; Shen L
    Hum Pathol; 2016 Sep; 55():182-9. PubMed ID: 27260946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinicopathological significance and prognostic role of tumor-infiltrating lymphocytes in colorectal cancer.
    Ko YS; Pyo JS
    Int J Biol Markers; 2019 Jun; 34(2):132-138. PubMed ID: 30852949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes.
    Kim A; Heo SH; Kim YA; Gong G; Jin Lee H
    Am J Clin Pathol; 2016 Jul; 146(1):137-44. PubMed ID: 27402610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer.
    Song M; Chen D; Lu B; Wang C; Zhang J; Huang L; Wang X; Timmons CL; Hu J; Liu B; Wu X; Wang L; Wang J; Liu H
    PLoS One; 2013; 8(6):e65821. PubMed ID: 23785454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological significance of PD-L1 expression in colorectal cancer: Impact of PD-L1 expression on pFOXO1 expression.
    Pyo JS; Ko SH; Ko YS; Kim NY
    Pathol Res Pract; 2020 Feb; 216(2):152764. PubMed ID: 31836325
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.